Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Mukhopadhyay, Asima
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. [electronic resource] - Cancer research Nov 2012 - 5675-82 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
1538-7445
10.1158/0008-5472.CAN-12-0324 doi
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carboplatin--administration & dosage
Carcinoma, Ovarian Epithelial
Combined Modality Therapy
DNA Breaks, Double-Stranded
Enzyme Inhibitors--administration & dosage
Female
Homologous Recombination
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasms, Glandular and Epithelial--drug therapy
Ovarian Neoplasms--drug therapy
Paclitaxel--administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. [electronic resource] - Cancer research Nov 2012 - 5675-82 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
1538-7445
10.1158/0008-5472.CAN-12-0324 doi
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carboplatin--administration & dosage
Carcinoma, Ovarian Epithelial
Combined Modality Therapy
DNA Breaks, Double-Stranded
Enzyme Inhibitors--administration & dosage
Female
Homologous Recombination
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasms, Glandular and Epithelial--drug therapy
Ovarian Neoplasms--drug therapy
Paclitaxel--administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors